about
Recent advances of biomaterials in biotherapyα, ω-Cholesterol-functionalized low molecular weight polyethylene glycol as a novel modifier of cationic liposomes for gene delivery.Antitumor and Adjuvant Activity of λ-carrageenan by Stimulating Immune Response in Cancer ImmunotherapyTreatment of dextran sodium sulfate-induced experimental colitis by adoptive transfer of peritoneal cells.Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase and cause subsequent inflammatory response.Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplexDichloroacetate induces protective autophagy in LoVo cells: involvement of cathepsin D/thioredoxin-like protein 1 and Akt-mTOR-mediated signaling.A folate receptor-targeted lipoplex delivering interleukin-15 gene for colon cancer immunotherapy.Simultaneous enhancement of cellular and humoral immunity by the high salt formulation of Al(OH)3 adjuvant.CRISPR/Cas9-Mediated Genome Editing of Epigenetic Factors for Cancer Therapy.Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors.Folate-Modified Lipoplexes Delivering the Interleukin-12 Gene for Targeting Colon Cancer Immunogene Therapy.Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.CRISPR/Cas9-mediated correction of human genetic disease.Cholesterol-modified Hydroxychloroquine-loaded Nanocarriers in Bleomycin-induced Pulmonary Fibrosis.The Current Status of Non-viral Vectors for Gene Therapy in China.Recent Advances in Therapeutic Genome Editing in China.In vivo ovarian cancer gene therapy using CRISPR-Cas9 system.Gene Therapy with Tetracycline-Regulated Human Recombinant COLIA1 cDNA Direct Adenoviral Delivery Enhances Fracture Healing in Osteoporotic Rats.Negative regulation of cationic nanoparticle-induced inflammatory toxicity through the increased production of prostaglandin E2 via mitochondrial DNA-activated Ly6C+ monocytes.Current Advances in Small Activating RNAs for Gene Therapy: Principles, Applications and ChallengesCurrent RNA-based Therapeutics in Clinical TrialsApplications of Genome Editing Technology in Animal Disease Modeling and Gene TherapyCarbon black nanoparticles induce cell necrosis through lysosomal membrane permeabilization and cause subsequent inflammatory responseThe approved gene therapy drugs worldwide: from 1998 to 2019Progress in the treatment of infantile hemangiomaFolate-Modified Liposomes Loaded with Telmisartan Enhance Anti-Atherosclerotic Potency for Advanced Atherosclerosis in ApoE-/- Mice
P50
Q26752054-3282BC47-60A4-4563-A7C7-B93524B56D58Q34685368-D0E17C33-24F6-4B03-AD9B-244401F9E236Q35766482-01AA2483-6415-4F91-A709-FB7363CBF5ABQ36275547-13256E40-7131-45FC-8701-1205D7018F63Q36293364-0BEE03C3-BB6A-479E-A925-1383F5F69D66Q36776863-C10F7E9C-2387-46A4-B7D3-F2BA1469BDDAQ37357063-D035CD76-7A4E-4A69-BF6E-0EBE1B5F131AQ37588429-8473959D-3785-4DFB-9CEA-FC89464BB598Q37743456-302E2E98-6A1E-44B0-8404-4F101CC120ECQ38527997-B95AAE77-C670-4FC3-8412-D46EDAB14FAFQ38547465-61009B93-C501-43FA-948C-AF70024D1C27Q38820548-6A96785F-132B-4B3B-A3FE-C0B419C48CB7Q39319380-2FA67404-8677-49ED-9596-3D3A8380870AQ39324185-4DD887D9-AE6C-489E-824C-D91A02EE709FQ41636898-DD502C13-5320-4954-9A3E-9DB6EBA86D0BQ47555976-2E182C5F-C20D-4CCE-92CF-01977332E0FEQ49982149-493438A4-42D2-4492-93A3-F64999AC72A0Q52394145-02CC12DB-5C89-4C5C-9876-ED6855B9CF6FQ54092428-B38BFDC2-C47D-4AC8-A254-523284F58051Q55265933-A39693F9-F629-477B-9341-7BDE3164D92CQ89156296-8243FBEA-159B-4FDB-AC33-528FC7198744Q90361781-8E149415-AAF0-4C2E-BFC0-15394BE41D10Q91866605-12D7AF8A-5C9E-48DE-B7F8-4494C21566C2Q91943313-E6470844-0883-47AC-A3C2-2E8286E02505Q92321995-E1317188-0F3E-4604-9A53-67249B7B2F17Q92593924-0EE009D2-1410-4871-A286-5B2F4424C969Q93334762-B4DE655C-59C0-4EC5-A48D-B5336E076DB1
P50
description
researcher ORCID ID = 0000-0001-7888-211X
@en
wetenschapper
@nl
name
Zhi-Yao He
@ast
Zhi-Yao He
@en
Zhi-Yao He
@es
Zhi-Yao He
@nl
type
label
Zhi-Yao He
@ast
Zhi-Yao He
@en
Zhi-Yao He
@es
Zhi-Yao He
@nl
prefLabel
Zhi-Yao He
@ast
Zhi-Yao He
@en
Zhi-Yao He
@es
Zhi-Yao He
@nl
P108
P1153
36025183400
P31
P496
0000-0001-7888-211X